Cramer: Why Covidien is Now a Buy
Now that Covidien is spinning off its pharmaceuticals business, the stock is a buy, “Mad Money” host Jim Cramer said Monday.
The company , which makes medical devices and supplies, announced last week that it intends to make its pharmaceutical business a standalone public company.
“This is all about streamlining Covidien so the company can focus on what it does best—devices,” Cramer said, pointing out that the new CEO comes from a medical device background within the company.
He also thinks the pharma division has been dragging the rest of the company down. It’s historically been a lot more volatile and has much lower margins than Covidien’s fast-growing medical device franchise.
“Covidien has been trying to remake itself for a long time,” Cramer said, “and spinning off the pharma business is just the latest step as the company transforms from a cash-cow like conglomerate into a faster-growing, more nimble, and more profitable medical technology business.”
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org